Showing results (111-120 of 214) with videos related to
Sort By:
Pageof 22
International Journal of Clinical Practice|November 24, 1999
Percutaneous ethanol injection therapy in 47 cirrhotic patients with hepatocellular carcinoma 5 cm or less: a long-term resultS M Lin, D Y Lin, C J LinChanggeng Yi Xue Za Zhi|March 1, 1995
Risk factors of hepatocellular carcinoma with familial tendencyY T Hung, D Y Lin, C T ChiuBiometrika|September 6, 2024
Maximum likelihood estimation for semiparametric regression models with interval-censored multistate dataYu Gu, Donglin Zeng, Gerardo Heiss, et al.Statistics in Medicine|July 15, 1997
Estimating the proportion of treatment effect explained by a surrogate markerD Y Lin, T R Fleming, V De GruttolaGenetic Epidemiology|June 6, 2007
Detecting haplotype effects in genomewide association studiesB E Huang, C I Amos, D Y LinBiometrics|September 29, 1998
Assessing the sensitivity of regression results to unmeasured confounders in observational studiesD Y Lin, B M Psaty, R A KronmalClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III StudyNicholas Thatcher, Jerome H Goldschmidt, Michael Thomas, et al.Metabolic Brain Disease|April 9, 2013
Transjugular intrahepatic portosystemic shunt induced short- and long-term cerebral blood flow variations in cirrhotic patients: an arterial spin labeling MRI studyGang Zheng, Long Jiang Zhang, Yue Cao, et al.The Journal of Infectious Diseases|February 1, 1997
Perspective: validating surrogate markers--are we being naive?V De Gruttola, T Fleming, D Y Lin, et al.Biometrics|June 1, 1997
Estimating medical costs from incomplete follow-up dataD Y Lin, E J Feuer, R Etzioni, et al.Pageof 22